Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$22.8M Buy
240,300
+175,800
+273% +$15.9M 0.02% 881
2014
Q2
$5.54M Buy
64,500
+44,900
+229% +$3.41M ﹤0.01% 1865
2014
Q1
$1.37M Sell
19,600
-199,200
-91% -$15.8M ﹤0.01% 3152
2013
Q4
$18.5M Buy
218,800
+137,200
+168% +$10.9M 0.02% 854
2013
Q3
$6.29M Buy
81,600
+51,000
+167% +$3.57M 0.01% 1516
2013
Q2
$1.79M Buy
+30,600
New +$1.84M ﹤0.01% 2665

Other funds holding CELG

UBS's CELG Position: Q3 2014 in Review

UBS increased its Celgene Corp (CELG) stake by 17% in Q3 2014, buying an estimated $44.3M and bringing the position to 3,396,963 shares worth $322M. The position accounts for 0.24% of the portfolio, ranked #81.

UBS first reported a position in CELG in Q2 2013 and has held it in 6 quarters since. 1,031 funds tracked by Wall St. Rank hold CELG as of Q3 2014.

  • UBS held 3,396,963 shares of Celgene Corp worth $322M as of Q3 2014.
  • UBS bought 490,488 Celgene Corp shares in Q3 2014, an estimated $44.3M.
  • Celgene Corp made up 0.24% of UBS's portfolio in Q3 2014, its #81 holding.
  • UBS first reported a position in Celgene Corp in Q2 2013 and has held it in 6 quarters since.
  • 1,031 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.